Insider · CIK 0001611756
Khursheed Anwer
Files at IMNN (Imunon, Inc.). First filing -, latest -.
In brief
Khursheed Anwer files SEC Form 4 as officer at IMNN (Imunon, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Khursheed Anwer has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +15,736 | $0.00 | $0 | 15,736 | Jan 6, 2026 |
| Aug 4, 2025 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,667 | $0.00 | $0 | 1,667 | Aug 6, 2025 |
| Mar 14, 2024 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Mar 18, 2025 |
| Mar 15, 2024 | IMNN Imunon, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 110,688 | Mar 18, 2024 |
Questions about Khursheed Anwer
Answered from the filings on this page, as of the latest one.
Is Khursheed Anwer buying or selling?
Khursheed Anwer has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Khursheed Anwer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Khursheed Anwer has 0.
Where does Khursheed Anwer file Form 4?
Khursheed Anwer has filed Form 4 at IMNN (Imunon, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.